PI 3-kinase p110 delta Antibody (29): sc-136032

PI 3-kinase p110δ Antibody (29) is a mouse monoclonal IgG1 antibody that detects phosphatidylinositol 3-kinase p110δ (PI 3-kinase p110δ) in mouse, rat, and human samples through applications such as western blotting (WB), immunoprecipitation (IP), and immunofluorescence (IF). PI 3-kinase p110δ is a critical enzyme involved in cellular signaling pathways that regulate various cellular functions, including growth, survival, and metabolism. PI 3-kinase p110δ is primarily located in the cytoplasm and is essential for the activation of downstream signaling cascades that influence cell proliferation and survival, making PI 3-kinase p110δ a vital component in the study of cancer and other diseases characterized by dysregulated cell growth. Notably, PI 3-kinase p110δ exists in two isoforms, with isoform 1 predominantly expressed in leukocytes and isoform 2 found in normal thymus, lung, and spleen tissues, highlighting PI 3-kinase p110δ importance in immune responses and tissue homeostasis. PI 3-kinase p110δ interaction with various proteins, including p85 regulatory subunits, underscores PI 3-kinase p110δ role in modulating signaling pathways, and understanding these interactions can provide insights into therapeutic targets for diseases associated with aberrant PI 3-kinase activity. Anti-PI 3-kinase p110δ antibody (29) is an invaluable tool for researchers investigating the complexities of cellular signaling and its implications in health and disease.

Alexa Fluor^® is a trademark of Molecular Probes Inc., OR., USA

LI-COR^® and Odyssey^® are registered trademarks of LI-COR Biosciences

PI 3-kinase p110 delta Antibody (29) References:

1. Conformational disruption of PI3Kδ regulation by immunodeficiency mutations in PIK3CD and PIK3R1.  |  Dornan, GL., et al. 2017. Proc Natl Acad Sci U S A. 114: 1982-1987. PMID: 28167755
2. Immune Dysregulation and Disease Pathogenesis due to Activating Mutations in PIK3CD-the Goldilocks' Effect.  |  Tangye, SG., et al. 2019. J Clin Immunol. 39: 148-158. PMID: 30911953
3. The delta isoform of phosphatidylinositol-3-kinase predominates in chronic myelomonocytic leukemia and can be targeted effectively with umbralisib and ruxolitinib.  |  Villaume, MT., et al. 2021. Exp Hematol. 97: 57-65.e5. PMID: 33617893
4. PIK3CD correlates with prognosis, epithelial-mesenchymal transition and tumor immune infiltration in breast carcinoma.  |  He, W., et al. 2023. Discov Oncol. 14: 187. PMID: 37861728
5. Tracheal epithelial cell-exosome-derived MiR-21-5p inhibits alveolar macrophage pyroptosis to resist pulmonary bacterial infection through PIK3CD-autophagy pathway.  |  Wang, J., et al. 2024. Life Sci. 336: 122340. PMID: 38092143
6. Rescuing the cytolytic function of APDS1 patient T cells via TALEN-mediated PIK3CD gene correction.  |  Poggi, L., et al. 2023. Mol Ther Methods Clin Dev. 31: 101133. PMID: 38152700
7. FAM76B regulates PI3K/Akt/NF-κB-mediated M1 macrophage polarization by influencing the stability of PIK3CD mRNA.  |  Wang, J., et al. 2024. Cell Mol Life Sci. 81: 107. PMID: 38421448
8. JAK3/STAT5 signaling-triggered upregulation of PIK3CD contributes to gastric carcinoma development.  |  Hu, Q., et al. 2024. J Cell Commun Signal. 18: e12017. PMID: 38545256
9. circZNF532 promotes endothelial-to-mesenchymal transition in diabetic retinopathy by recruiting TAF15 to stabilize PIK3CD.  |  Fu, XL., et al. 2024. Endocr J. 71: 675-686. PMID: 38811189
10. CHF6523 data suggest that the phosphoinositide 3-kinase delta isoform is not a suitable target for the management of COPD.  |  Govoni, M., et al. 2024. Respir Res. 25: 380. PMID: 39427187

The preferred PI 3-kinase p110δ antibody is PI 3-kinase p110δ Antibody (A-8): sc-55589.